QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release ...

Tenecteplase failed to outperform aspirin for vision recovery when administered within 4.5 hours of onset of acute central ...

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

Understand the evolving practices in antimicrobial therapy, emphasizing shorter antibiotics without compromising outcomes.

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

In the new American guideline for early management of acute ischemic stroke (AIS), mechanical thrombectomy is expanded, ...

Acute stress disorder occurs three days to four weeks after trauma. Discover how to recognize symptoms and find help for you ...

A significant medical achievement was recorded at Sultan Qaboos University Hospital in the management of acute poisoning. A ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...